Transcriptomic and Genetic Endotyping of Exacerbation-Prone Asthmatics

易加重哮喘的转录组学和基因内型分析

基本信息

  • 批准号:
    10009466
  • 负责人:
  • 金额:
    $ 42.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-01 至 2022-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Human rhinovirus (HRV) infection of the upper airways is one of the strongest environmental risk factors for childhood asthma exacerbations. However, not all children experience an acute exacerbation in response to HRV infection. In fact, the asthmatic population is stratified into exacerbation-prone and exacerbation-resistant patients. Variability in patient cellular responses to virus infection could explain the exacerbation risk stratification observed in childhood asthmatics. The nasal airway epithelium is the primary site of HRV infection and replication, suggesting the importance of nasal epithelial responses to HRV. We hypothesize that heterogeneity exists in asthmatic airway pathobiological mechanisms (endotypes), some of which may predispose to exacerbations. Supporting this we find that high nasal gene expression levels of IL-13, a marker of the type 2-high asthma endotype, are associated with exacerbation risk. The response to virus of the airway epithelium is likely driven by the molecular state of the airway epithelium. Both endogenous immune (IL-13) and inhaled environmental exposures (environmental tobacco smoke (ETS)) can greatly alter the transcriptome profile of the airway epithelium. Additionally, recent studies have found genetic variants that affect airway gene expression predispose to childhood asthma exacerbations. Therefore, we hypothesize that an immune and/or environmentally “primed” airway epithelium responds in a dysregulated way to viral infections, resulting in asthma exacerbations among genetically predisposed subjects. To test these hypotheses we propose the following aims: Aim 1: Determine if type 2 cytokine high and other nasal expression endotypes are associated with exacerbation-prone asthma and predict occurrence of asthma exacerbations. We will perform whole transcriptome sequencing (WTS) of nasal airway brushings from children with asthma that are exacerbation-prone (n=100), exacerbation-resistant (n=100), and healthy control subjects (n=100). We will identify genes, pathways, and expression endotypes that are associated with exacerbation- prone asthma. Aim 2: Determine how IL-13 and ETS stimuli modify the transcriptome response of nasal epithelial cells (NECs) to HRV infection and if these responses vary by exacerbation-prone asthma status. Air- liquid interface NEC cultures from Aim 1 donors will be treated with mock-stimulus, IL-13, ETS, HRV-A,-C or primed with IL-13 or ETS and then infected with HRV-A or -C. WTS gene expression data generated from these cultures will be used to identify differentially expressed genes by treatment. The treatment responses will be analyzed in a synergy/antagonism analysis to identify HRV infection responses that are perturbed by IL-13 or ETS pretreatment. Aim 3: We will identify in vivo airway epithelium expression quantitative trait loci (eQTL) variants in exacerbation-prone asthma genes. We will determine genetic variants that interact with immune/environmental stimulated airway epithelium to drive deleterious epithelial responses to HRV infection (response eQTLs). We will determine eQTL/reQTL variants that confer risk of exacerbation-prone asthma.
项目总结/摘要 上呼吸道的人鼻病毒(HRV)感染是呼吸道感染的最强环境风险因素之一。 儿童哮喘恶化。然而,并不是所有的儿童都经历急性加重, HRV感染。事实上,哮喘人群分为易加重和难加重 患者患者细胞对病毒感染反应的变异性可以解释急性加重风险 在儿童哮喘患者中观察到的分层。鼻气道上皮是HRV感染的主要部位 和复制,提示鼻上皮对HRV反应的重要性。我们假设 哮喘气道病理生物学机制(内型)存在异质性,其中一些可能 容易恶化。支持这一点,我们发现鼻基因表达水平高的IL-13,一个标志物, 2型-高哮喘内型,与急性发作风险相关。呼吸道对病毒的反应 上皮细胞可能由气道上皮细胞的分子状态驱动。内源性免疫(IL-13) 和吸入的环境暴露(环境烟草烟雾(ETS))可以大大改变 气道上皮的转录组谱。此外,最近的研究发现, 影响气道基因表达易导致儿童哮喘恶化。因此,我们假设 免疫和/或环境“致敏”的气道上皮以失调的方式对病毒应答 感染,导致遗传易感受试者的哮喘恶化。测试这些 目的1:确定是否2型细胞因子高和其他鼻分泌物 表达内型与易加重哮喘相关并可预测哮喘的发生 加重我们将对儿童的鼻气道刷拭物进行全转录组测序(WTS) 易加重(n=100)、难加重(n =100)的哮喘患者和健康对照受试者 (n=100)。我们将确定与急性加重相关的基因、途径和表达内型- 容易哮喘目的2:确定IL-13和ETS刺激如何改变鼻粘膜细胞的转录组反应。 上皮细胞(NEC)对HRV感染的反应,以及这些反应是否因易加重的哮喘状态而异。空气- 来自Aim 1供体的液体界面NEC培养物将用模拟刺激、IL-13、ETS、HRV-A、-C或 用IL-13或ETS致敏,然后用HRV-A或HRV-C感染。WTS基因表达数据来自 这些培养物将用于鉴定通过处理差异表达的基因。治疗反应将 在协同/拮抗分析中进行分析,以鉴定受IL-13干扰的HRV感染应答 或ETS预处理。目的3:筛选体内气道上皮表达的数量性状基因座(eQTL) 易加重哮喘基因的变异。我们将确定基因变异, 免疫/环境刺激的气道上皮对HRV感染产生有害的上皮反应 (响应eQTL)。我们将确定eQTL/reQTL变异,赋予哮喘加重倾向的风险。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Max A Seibold其他文献

The Child Opportunity Index 2.0 and exacerbation-prone asthma in a cohort of urban children.
城市儿童队列中的儿童机会指数 2.0 和易加重哮喘。
  • DOI:
    10.1002/ppul.26998
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    3.1
  • 作者:
    E. H. Skeen;Camille M Moore;Monica J Federico;Max A Seibold;Andrew H Liu;Katharine L. Hamlington
  • 通讯作者:
    Katharine L. Hamlington
The Puerto Rican Infant Metagenomic and Epidemiologic Study of Respiratory Outcomes (PRIMERO): Design and Baseline Characteristics for a Birth Cohort Study of Early-life Viral Respiratory Illnesses and Airway Dysfunction in Puerto Rican Children
波多黎各婴儿呼吸系统结果宏基因组和流行病学研究 (PRIMERO):波多黎各儿童早期病毒性呼吸道疾病和气道功能障碍的出生队列研究的设计和基线特征
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Jonathan I Witonsky;J. Elhawary;C. Eng;Sam S Oh;S. Salazar;M. G. Contreras;V. Medina;Elizabeth A Secor;Priscilla Zhang;J. Everman;A. Fairbanks;E. Pruesse;S. Sajuthi;Chih;Tsunami Rosado Guerrero;Keyshla Canales Fuentes;Natalie Lopez;C. A. Montanez;Richeliz Alfonso Otero;Raymarie Colon Rivera;Leysha Rodriguez;Gabriela Vazquez;D. Hu;S. Huntsman;Nathan D. Jackson;Yingchun Li;Andrew Morin;Natalie A Nieves;C. Rios;Gonzalo Serrano;Blake J M Williams;E. Ziv;Camille M Moore;D. Sheppard;E. Burchard;Max A Seibold;J. R. Rodríguez Santana
  • 通讯作者:
    J. R. Rodríguez Santana
FIRST Association Between the MUC 5 B Promoter Polymorphism and Survival in Patients With Idiopathic Pulmonary Fibrosis
FIRST MUC 5 B 启动子多态性与特发性肺纤维化患者生存之间的关联
  • DOI:
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    0
  • 作者:
    A. Peljto;Yingze Zhang;T. Fingerlin;Shwu;Joe G. N. Garcia;T. Richards;Lori J. Silveira;K. Lindell;M. Steele;James E. Loyd;K. Gibson;Max A Seibold;Kevin K. Brown;Janet L. Talbert;C. Markin;K. Kossen;S. Seiwert;Elissa Murphy;I. Noth;Marvin I. Schwarz;N. Kaminski;David A. Schwartz
  • 通讯作者:
    David A. Schwartz
Asthma severity and corticosteroid response depend on variable type 1 and type 2 inflammation in the airway
哮喘严重程度和皮质类固醇反应取决于气道中不同的 1 型和 2 型炎症
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    J. Fahy;Nathan D. Jackson;S. Sajuthi;E. Pruesse;Camille M Moore;J. Everman;C. Rios;M. Tang;Marc Gauthier;S. Wenzel;E. Bleecker;Mario Castro;S. Comhair;S. Erzurum;A. Hastie;Wendy C Moore;Elliot Israel;Bruce D. Levy;L. Denlinger;N. Jarjour;M. Johansson;David T. Mauger;B. Phillips;K. Sumino;Prescott G. Woodruff;M. Peters;Max A Seibold
  • 通讯作者:
    Max A Seibold

Max A Seibold的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Max A Seibold', 18)}}的其他基金

Transcriptomic and Genetic Endotyping of Exacerbation-Prone Asthmatics
易加重哮喘的转录组学和基因内型分析
  • 批准号:
    9359963
  • 财政年份:
    2017
  • 资助金额:
    $ 42.95万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10009470
  • 财政年份:
    2017
  • 资助金额:
    $ 42.95万
  • 项目类别:
Defining Molecular Phenotypes of Exacerbation Prone Asthmatics
定义易加重哮喘的分子表型
  • 批准号:
    10009452
  • 财政年份:
    2017
  • 资助金额:
    $ 42.95万
  • 项目类别:
Defining Molecular Phenotypes of Exacerbation Prone Asthmatics
定义易加重哮喘的分子表型
  • 批准号:
    10246163
  • 财政年份:
    2017
  • 资助金额:
    $ 42.95万
  • 项目类别:
Transcriptomic and Pharmacogenetic Asthma Endotypes in Minority Children
少数民族儿童哮喘内型的转录组学和药物遗传学
  • 批准号:
    10166900
  • 财政年份:
    2017
  • 资助金额:
    $ 42.95万
  • 项目类别:
Transcriptomic and Genetic Endotyping of Exacerbation-Prone Asthmatics
易加重哮喘的转录组学和基因内型分析
  • 批准号:
    10246165
  • 财政年份:
    2017
  • 资助金额:
    $ 42.95万
  • 项目类别:
Genetic Control of Airway Epithelium Gene Expression in Childhood Asthmatics
儿童哮喘气道上皮基因表达的遗传控制
  • 批准号:
    9120408
  • 财政年份:
    2015
  • 资助金额:
    $ 42.95万
  • 项目类别:
Genetic Control of Airway Epithelium Gene Expression in Childhood Asthmatics
儿童哮喘气道上皮基因表达的遗传控制
  • 批准号:
    8941629
  • 财政年份:
    2015
  • 资助金额:
    $ 42.95万
  • 项目类别:
Transcriptomic and Genetic Endotyping of Exacerbation-Prone Asthmatics
易加重哮喘的转录组学和基因内型分析
  • 批准号:
    9766952
  • 财政年份:
  • 资助金额:
    $ 42.95万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.95万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.95万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 42.95万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.95万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 42.95万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.95万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.95万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.95万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 42.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 42.95万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了